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Abstract
Background: Lower respiratory tract infections (LRTIs) are a major cau-
se of morbidity and mortality globally. The World Health Organization 
(WHO) estimates that LRTIs are the most common global cause of 
death from infectious diseases. However, the specific etiologic agent 
associated with LRTI is often unknown. We determined the bacterial 
infections and seasonal patterns associated with LRTIs among hospita-
lized cases at Jordan University Hospital (JUH) for a period of five years. 
Methods: We conducted a retrospective multi-year study among hos-
pitalized patients in Jordan on LRTI-associated bacterial etiology. 
Results: We found bacterial infections among 105 (21.1%) out of 495 
LRTI patients. The most frequently identified bacteria in the LRTI pa-
tients were Staphylococcus aureus (7.7%) followed by Pseudomonas 
aeruginosa (5.1%). Most of the LRTI patients (95.2%) had at least one 
chronic disease and many were admitted to the Intensive Care Unit 
(16.8%). Of the 18(3.64%) patients with LRTIs who died at the hospital, 
2 had a bacterial infection. We noticed a seasonal pattern of bacterial 
infections, with the highest prevalence during the winter months. 
Conclusions: Our findings suggest that early identification of bacterial 
agents and control of chronic disease may improve clinical manage-
ment and reduce morbidity and mortality from LRTIs. 
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Introduction
Lower respiratory tract infections (LRTIs) continue to 
be a major cause of morbidity and mortality world-
wide. The World Health Organization (WHO) esti-
mates that LRTIs, including pneumonia and acute 
bronchitis,cause about 3.5 million deaths global-
ly per year [1]. Community-acquired pneumonia 
(CAP) is a severe form of LRTI that can progress 
to a critical condition requiring hospitalization. It 
can be life-threatening, especially for the elderly 
with chronic diseases and can quickly turn fatal [2]. 
Adult CAP can be caused by abroad spectrum of 
etiological agents including bacteria. However, by 
far, Streptococcus pneumoniae has been found to 
be the most common bacteria in CAP cases. For 
example, a review of 41 European studies found 
S. pneumoniae to be the most prevalent bacteria 
among CAP cases [3-6], followed by Mycoplasma 
pneumoniae, Chlamydia pneumoniae, Legionella 
pneumophila, and Haemophilus influenzae, while 
Staphylococcus aureus was the least common 
among studied bacteria as a causative agent of CAP 
[6]. A meta-analysis involving 38 studies from Asia 
also showed a similar pattern with S. pneumoniae 
being the most common pathogen identified in LRTI 
(13.3%), followed by M. pneumoniae, and H. influ-
enzae. On the other hand, Staphylococcus aureus 
was isolated only in 4.0% of patients [7]. Relative-
ly little is known about bacterial infection among 
CAP patients in Jordan. Consistent with findings 
from other parts of the world, a single study in 
Jordan among only 35 adult CAP patients reported 
S. pneumoniae to be the most common bacteria 
(26%), followed by C. pneumoniae (23%) and H. 
influenzae (17%) more than a decade ago [8]. Since 
then, no study has been conducted on the recent 
trends of bacterial infection among LRTI cases in 
Jordan. 
Therefore, it is critical to have information on the 
etiological agents associated with LRTI in Jordan 
and the surrounding region for a number of rea-
sons. First, in many countries of the region, antibiot-
ic resistance is increasing [9], particularly against S. 
pneumoniae [10]. Second, there is increased varia-
tion of causative bacteria in infections, contributed 
to by extensive and unregulated antibiotic use, and 
the introduction of vaccines against pneumococcal 
antigens [7]. Third, the pattern of causative agents 
may differ by geographic area due to seasonal vari-
ations [11]. To address the above issues, we have 
conducted for the first time a large multi-year study 
among hospitalized patients in Jordan on LRTI-asso-
ciated bacterial etiology. The findings of the study 
will provide information on the trends of bacterial 
agents causing LRTI in Jordan, help clinical manage-
ment with the appropriate use ofantibiotics, and 
ultimately reduce the burden of morbidity and mor-
tality from LRTI in the region.
Method
Data collection and study design
Jordan University Hospital (JUH) is a teaching hos-
pital in the north of Amman, the capital of the 
Hashemite Kingdom of Jordan. Study subjects 
were patients admitted by the pulmonary medicine 
and critical care primary team from January 2011 
to January 2016. The LRTI cases were defined as 
having cough, purulent sputum, dyspnoea, thoracic 
pain, fever, chills, myalgia, and confusion [12].The 
LRTI cases were sub-typed into acute bronchitis and 
pneumonia. Acute bronchitis was defined as the 
presence of fever (>38°C), cough, increased spu-
tum production, rhonchi, and wheezing, with no 
radiographic evidence of pneumonia. Pneumonia 
was defined by new or progressive lung infiltrate 
(i.e., increased density on chest X-ray due to the 
presence of pus, protein, or air within the parenchy-
ma of the lung), consolidation, pleural effusion, or 
cavitations on chest X-ray along with the symptoms 
of acute bronchitis [13]. We documented vital signs, 
such as temperature, heart rate, blood pressure, res-
piratory rate, and their level of consciousness. We 
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also reviewed the study participants’current and 
past medical histories, including chronic diseases. 
Data on demographics and smoking were collected 
from their medical records. We also recorded the 
patients’ date of admission, to identify possible sea-
sonal patterns.
As a part of this analysis, we examined the pa-
tients’ chest X-rays, to identify any radiologic chan-
ges. Blood culture and sputum culture were done 
for all patients and were the primary method for 
identifying the bacterial agents. In addition, urinary 
antigens were tested for S. pneumoniae and Le-
gionella spp [14, 15].
Collection and isolation of bacteria
First, laboratory personnel performed Gram stain-
ing on all specimens, then bacterial cultures were 
prepared for two different growth conditions, one 
for aerobic and the other for anaerobic bacteria, 
in the BacT/Alert system (OrganonTeknika Corp., 
Durham, N.C.) [16]. If the culture was positive for 
anaerobic bacteria, blood agar plates were used as 
differential media. CLED agar was used for select-
ed Gram-negative bacteria and chocolate agar for 
fastidious bacteria, such as Haemophilus influenzae 
and Neisseria meningitidis. As of 2015, we used 
a multiplex polymerase chain reaction (PCR) res-
piratory panel for the detection of Streptococcus 
pneumoniae, Haemophilus influenzae, Moraxella 
catarrhalis, Legionella pneumophila, Legionella 
longbeachae, Mycoplasma pneumoniae, and Chla-
mydia pneumoniae, since the detection rate by PCR 
is significantly higher than culture methods [17].
The severity of pneumonia
We classified the severity of LRTI in our study popu-
lation using the Confusion, Blood Urea Nitrogen, 
and Blood pressure (CURB-65) score [18]. CURB-65 
is a clinical quantification scale that has been valid-
ated for predicting mortality in community-acquired 
pneumonia [19] and infection of any site [19]. CURB-
65 has been recommended by the British Thoracic 
Society for assessing the severity of pneumonia 
[20]. A severity score for CURB-65 is estimated by 
adding 1 point for the following risk factors:confu-
sion, blood urea nitrogen >7 mmol/L, respiratory 
rate ≥30 breaths/min, systolic blood pressure ≤90, 
diastolic blood pressure ≤60 mmHg and for individ-
ual’s age 65 years or older. We reviewed the end-
points of the outcome including improvement and 
hospital discharge, death and recurrent admission 
and whether they had developed complications, 
including intubation for acute respiratory distress 
syndrome (ARDS), respiratory failure, and other 
complications like pleural effusion, septic shock, 
disseminated intravascular coagulation (DIC), myo-
cardial infarction (MI), or renal complications.
Statistical analysis 
We used SPSS software for analyzing the collected 
data (SPSS Inc., Chicago, Illinois, USA). We applied 
the Pearson Chi-squared test (X2 test) and t-test to 
compare groups with categorical and continuous 
variables respectively. The analysis compared bet-
ween pneumonia and acute bronchitis in their 
etiology, outcomes, and mortality rates. Statistical 
significance for the results in all these two-tailed 
statistical tests was p<0.05.
Results 
Patients’ characteristics
This study included 495 patients. The average age 
of the study participants was 58 years (range 13-
92). Males (57.9 ± 19.3) were slightly older than 
females (57.7 ± 17.3). There were 55 % males and 
45% females. Out of the 495 patients, 115 were cu-
rrent smokers (23%), 242 were non-smokers (49%), 
60 were ex-smokers (12%), and 78 patients (16%) 
did not specify their smoking habits. In this study, 
411 (83%) of the patients had at least one chronic 
illness, with 57% having multiple comorbidities. Pul-
monary diseases were present in 216 (44%) patients 
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and diabetes mellitus (DM) was among 191 patients 
(39%) (Table 1). 
Clinical diagnosis of LRTIs
More than half of the patients were diagnosed with 
pneumonia (59%) and the rest (41%) with acute 
bronchitis. The mean CURB-65 score was 1.3 ± 0.9. 
Of the 495 patients, 49 patients (10%) developed 
complications during hospitalization, with some 
patients developing more than one complication 
concurrently. The complications were as follows: 26 
(5.3%) patients developed pleural effusion, 4 (0.8%) 
myocardial infarction (MI), 6 (1.2%) septic shock, 5 
(1%) renal complications, and 2 (0.4%) developed 
disseminated intravascular coagulation (DIC). We 
found more patients with pneumonia (73.5%) had 
developed a complication as compared to those 
with acute bronchitis (p=0.02) during hospitaliza-
tion. A total of 83/495 (17%) patients were admit-
ted to the intensive care unit (ICU), and 18 (3.64%) 
of these patients died during hospitalization. 
Bacterial isolates analysis
A total of 105 (21.1%) bacteria isolates were de-
tected in investigated LRTI patients (Table 2). The 
most frequently identified bacteria species was S. 
aureus (7.7%), followed by P. aeruginosa (5.1%), 
Klebsiella spp. (3.2%) and Acinetobacterspp (2.2%). 
S. Pneumoniae was identified in 0.8% of cases. 
Other Gram-negative bacteria were identified in 
4.2% of the cases. P. aeruginosa was significantly 
associated with acute bronchitis cases (p = 0.01) 
(Table 3). The pattern of antibiotic resistance among 
predominant bacteria isolated from patients admit-
Table 2.  Causative agents identified among LRTI 
cases.
Clinical Characteristics No. of Patients Percent
Pathogen identified 157 31.7
Bacteria 105 21.2
Staphylococcus aureus 35 7.7
Pseudomonas aeruginosa 25 5.1
Klebsiellas pp. 16 3.2
Acinetobacter spp. 11 2.2
Streptococcus pneumoniae 4 0.8
Viral agents* 69 13.9
*: Reported in reference 37.
Table 3.  Comparison between bacterial causative 
agents of pneumonia and acute bronchitis.
Causitive 
Agent
Pneumonia
Acute 
Bronchitis Total P
ValuePositive Positive
n % n % n
S. aureus 20 57.1 15 42.9 35 0.69
P. aeruginosa 9 36 16 64 25 0.01
Klebsiella spp. 7 43.8 9 56.2 16 0.16
Acinetobacter 
spp.
5 45.5 6 54.5 11 0.37
S. pneumoniae 1 25 3 75 4 -
Table 1. Patients demographics.
Patient Characteristics No. of Patients Percent
Age (years)
Mean Age + SD (yr)
57.79 ± 18.43 
range (16-92)
Median Age 62 years
Gender
Male 274 55.4 
Female 221 44.6 
Smoking
Current Smoker 115 23.2 
Ex-Smoker 60 12.1 
Non-Smoker 242 48.9 
Unknown 78 15.8 
Co-morbidities 411 83.0 
Cardiovascular Diseases 272 55.0 
Pulmonary diseases 216 43.6 
Diabetes Mellitus 191 38.6 
Renal Diseases 57 11.5 
Other co morbidities 142 28.7 
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ted for LRTI is presented in Table 4. We classified the 
patients based on their month of admission in order 
to investigate seasonal variation (Figure 1). Interest-
ingly, S. aureus was found to have a peak incidence 
in January and November, following the same trend 
as viral LRTI Figure 2.
ICU case analysis
A majority of the patients (57; 69%) admitted to 
the ICU had pneumonia, while the rest (26; 31%) 
Table 4.  Antibiotic resistance pattern of predomi-
nant bacteria isolated from patients admit-
ted for LRTI.
Antibiotic
Bacteria
P. 
aeruginosa
Klebsiela 
spp.
Acinetobacter
Spp 
% % %
Tigecycline 33.3 16.7 15.4 
Gentamicin 33.3 33.3 30.8 
Cefotaxime 16.7 50.0 84.6 
Cefoxitin 16.7 41.7 92.3 
Ceftriaxone 16.7 58.3 84.6 
Ertapenem 16.7 41.7 76.9 
Amikacin 16.7 33.3 61.5 
Cefepime 33.3 58.3 76.9 
Ceftazidime 41.7 58.3 69.2 
Ciprofloxacin 50.0  50.0 76.9 
Imipenem 16.7 16.7 84.6 
Aztreonam 25.0 50.0 84.6 
Meropenem 25.0 50.0 76.9 
Piperacillin/
Tazobactam
25.0 50.0 76.9 
Colistin Sulphate 8.3 33.3 7.7 
S. pneumoniae S. aureus
% %
Ampicillin 100 92 
Chlormphenicol 0 4 
Clindamycine 100 28 
Erythromycine 100 64 
Levofloxacin 0 48 
Linexolide 0 8 
Oxacillin 100 52 
Tigacycline 0 8 
Vancomycin 0 0 
Gentamycin 100 24 
Figure 1:  Monthly distribution of the most preva-
lent bacterial causative agents of LRTI: 
This figure shows the monthly distribu-
tion of S. aureus, P. aeruginosa, and 
Klebsiella spp.
Figure 2:  The monthly variation of Staphylococcus 
LRTI and its relationship with the monthly 
variation of viral LRTI. Both S. aureus and 
viral LRTI peaked in January and followed 
the same seasonal variation.
The InTernaTIonal arabIc Journal of anTImIcrobIal agenTs 
ISSN: 2174-9094
2019
Vol. 9 No. 3:3
doi: 10.3823/837
This article is available at: www.iajaa.org / www.medbrary.com 6
had acute bronchitis. The average age of the pa-
tients admitted to ICU was higher (68 ± 16.7 years) 
than the rest of the study participants (56.5 ± 18.5 
years) and the majority of them were males (61%). 
As expected, the average CURB-65 score for the 
ICU patients were significantly higher than those 
at inpatient wards (2.11 and 1.16, respectively (p< 
0.0001). A causative agent of LRTIs was identified in 
37.3% of patients admitted to the ICU, with 26.5% 
of patients testing positive for bacterial agents. The 
most frequently identified causative agents were 
Klebsiella spp., P. aeruginosa, and S. aureus. Each 
of these bacterial species was identified in 6 cases 
(7.23%), followed by other Gram-negative bacteria, 
which were identified in 5 cases (6%). Acinetobac-
ter spp. was identified in 3 cases (3.61%), while 
S. pneumoniae and Burkholderia spp. were each 
isolated from only one ICU patient (1.2%).
When comparing the causative agents between 
pneumonia and acute bronchitis in ICU patients, 5 
(8.8%) of the pneumonia patients were infected 
with Klebsiella spp., 5 (8.8%) were infected with 
S. aureus, 4 (7%) patients had P. aeruginosa and 
3(5.3%) patients had other Gram-negative bac-
teria infections. On the other hand, only one of 
those diagnosed with acute bronchitis was infected 
with Klebsiella spp., additionally, one patient had 
S. aureus, 2 (7.7%) patients had P. aeruginosa and 
2 (7.7%) patients had Gram-negative bacteria as 
the causative agent. Most of the patients in the 
ICU (95%) had at least one chronic comorbidity in-
cluding cardiovascular diseases in 59 (71.1 %), 41 
(49.4%) had DM, 31 (37.3%) (Table 1). Pulmonary 
and renal diseases were presented in 16 (19.3%) 
of the patients. Complications were developed in 
22/83 (26.5%) of the patients admitted to ICU, and 
of these, 14 patients (16.9%) died and which repre-
sented 78% of all deaths in our study. 
Analysis of fatal cases
The total number of patient deaths associated with 
LRTI in our study was 18 (3.64%) patients out of 
495 patients with LRTI over five years. Of the fatal-
ities, 14 (77.8%) patients died from pneumonia 
and the other 4 (22.2%) from acute bronchitis. The 
median age at death was 70 years; 10 (55.56%) 
of them were males. Of the 18 patients who died, 
17 (94.4%) had comorbidities; 10 (55.6%) had DM, 
and 9 (50%) had cardiac disease. 
The mean CURB-65 score of death cases was 2.11 
± 0.83, which is significantly higher than the CURB-
65 score of living cases, which was 1.29± 0.89 (p 
= 0.001).The identified bacterial causative agents of 
the death cases have shown that the two patients 
had a bacterial infection (11.1%).
Discussion 
To our knowledge, this is the first large multi-year 
study in Jordan to determine bacterial agents associ-
ated with LRTI. Identification of the pathogens caus-
ing LRTI constitutes the basis for the selection of em-
pirical antimicrobial treatment, which improves the 
outcome of LRTI patients [21]. The most commonly 
isolated bacterial agent for LRTI at our hospital was 
S. aureus (7.7%), followed by P. aeruginosa (5.1%) 
and Klebsiella spp (3.2%). In comparison, the most 
commonly identified bacterial causative agent for 
LRTI was S. pneumoniae in Asia and Europe [6,7]. 
Our findings show a different pattern of causative 
agents than an earlier study in Jordan, where S. 
pneumoniae was the most commonly isolated bac-
teria (26%), followed by C. pneumoniae (23%), H. 
influenzae (17%), M. pneumoniae (9%), Legionella 
pneumophila (6%) and Klebsiella spp. (6%). In addi-
tion, most of the Gram-negative isolates were from 
patients who had comorbid conditions [8]. The pre-
vious study in Jordan was conducted only among 
35 cases in 2006. The differences in findings could 
be due to a change of prevalence of the causative 
agents of LRTI [8], the wide use of antibiotics in Jor-
dan without prescription in recent years [22]. Since 
then, the pneumococcal vaccines has also be intro-
duced in Jordan. The administration of pneumo-
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coccal vaccines was found to reduce antimicrobial 
resistance and the burden of pneumonia-associated 
hospitalizations on the healthcare system [23, 24]. 
The incidence of S. pneumoniae as a causative 
agent for LRTI was 0.8% in our study, which is ap-
proximately equal to the rates found in Srinagar/ 
India, in 2010 (1%) [23]. The difference in 
the causative agents of infection in different coun-
tries was proposed to be a result of the frequent 
use of antibiotics, changes in environmental pollu-
tion [25]. Upon comparison between the causative 
agents of pneumonia and acute bronchitis, P. aeru-
ginosa was significantly associated with acute bron-
chitis cases in our study. This finding is contradictory 
to the results of previous studies that classified them 
as common causative agents of pneumonia [26].
Antimicrobial resistance is an issue of significant 
concern worldwide. About two-thirds of all anti-
biotics prescriptions are for respiratory tract infec-
tions, and the lack of knowledge regarding micro-
biological aetiology may increase the influence of 
patient demand in addition to other non-clinical 
factors, leading to an increase of inappropriate anti-
biotic prescription [27]. A recent study conducted 
in Jordanian patients with otitis external infection 
emphasizing on the pathogenic characteristics of 
P. aeruginosa isolates showed that each of ceftazi-
dime, ciprofloxacin, imipenem and azetreonam had 
high to moderate susceptibility to P. aeruginosa in 
the range of (82-68%), respectively. Gentamicin 
and amikacin had high rates of resistance in the 
range of (72-57%) respectively. Only one isolate 
was resistant to colistin (3%) [28]. Our results dem-
onstrated 50% resistance for ciprofloxacin, while 
2 isolates of P. aeruginosa were colistin- resistant 
(8.3%). These results are alarming, especially with 
the presence of previous evidence of multi-drug re-
sistant P. aeruginosa [29].
S. aureus and S. pneumoniae showed high rates 
of resistance to ampicillin (92%, 100% respectively). 
On the other hand, all isolates of S. aureus and S. 
pneumoniae were susceptible 
for vancomycin. Recent studies showed high rates 
of methicillin-resistant S. aureus (MRSA) among Jor-
danian patients, necessitating careful evaluation of 
antimicrobial susceptibility results of isolates in vitro 
prior to prescribing antimicrobial agents [30].
Upon observing theseasonal variation, we found 
that bacterial LRTI peaked in January. In comparison, 
a study carried out in Iraq has shown that February 
was the peak month and August had the fewest 
admissions due to LRTI [31]. In our study, S. aureus 
infection, in particular, peaked in January, while P. 
aeruginosa peaked in March and Klebsiella spp. 
peaked in both March and September. In general, 
pneumonia incidence varies throughout the year, 
and it occurs more commonly in the seasons of 
winter and autumn [32, 33], with the highest num-
ber of deaths taking place during winter months 
[34]. This can be explained by the strong wind and 
relative humidity that aid in spreading airborne 
microorganisms. Additionally, in low temperatures, 
inhibition or competition between different types 
of microorganisms is weak, allowing more species 
to coexist in the atmosphere [35]. However, even 
though the impact of seasonality on the dynamics 
of bacterial agents causing LRTIs is gaining interest, 
LRTI should not be considered as a seasonal disease 
since it occurs throughout all seasons [36]. 
In a previous study conducted at Jordan Univer-
sity Hospital during the same timeframe, investigat-
ing the etiology of viral respiratory tract infections 
in Jordanian patients between 2011 and 2016, Fast-
track Diagnostics (FTD)® Respiratory21 Kit (Fast-track 
Diagnostics, Junglinster, Luxembourg) real-time PCR 
was used for 170 patients, and they were positive 
for seasonal Influenza A virus in 7.1% of patients, 
influenza B in 4.1%, Parainfluenza virus in 7.6%, 
RSV in 4.7%, adenovirus in 4.1%, metapneumo-
virus in 4.1%, coronavirus 229E/NL63 in 4.1%, and 
rhinovirus in 3.5%. Rapid test PCR (RT-PCR; Cepheid 
GeneXpert®, Sunnyvale,California, USA) was done 
for 495 patients, and the percent of cases who were 
positive for H1N1pdm009 virus was 4.2% [37].
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Furthermore, we found that viral infections and S. 
aureus infections follow the same trend of season-
al variation. Pneumonia caused by S. pneumoniae 
and S. aureus are a known life-threatening com-
plication of seasonal influenza [38-42], suggesting 
that S. pneumoniae and S. aureus infections may 
represent complicated influenza LRTI that requires 
special attention in order to decrease the risk of 
further morbidity and mortality.
One of the primary aims of the healthcare sys-
tem is to reduce the morbidity and mortality of 
the patients. In our study, 16.8% of patients were 
admitted to the ICU, and overall 9.9% of the 495 
developed complications related to their LRTI. The 
mortality rate of LRTI in our study was 3.64%, 
which is very similar to the mortality rate found in 
Japan (3.1%) in a study published in 2013 [43], while 
it reached approximately 10% in a study published 
2006 in Germany [44], and which is around the 
average in-hospital mortality of CAP [45]. The low 
mortality rate in Jordan may be due to the death 
of critical patients before presentation to hospitals, 
or death soon after the presentation of symptoms, 
before specimens can be collected [46]. The higher 
rate reported in Germany can be attributed to the 
high incidence of S. pneumoniae [47], as well as 
due to the presence of pneumococci, Legionella or 
Enterobacteriaceae infections, which were associ-
ated with increased risk of mortality [44]. DM was 
the most common comorbidity in the patients who 
died in our study since it was present in 10/18 pa-
tients (55%) who died. This supports the rationale 
that the management approach of LRTIshould be 
based on the associations between age, comorbid-
ity, etiology, and severity [48].
Since the mean age of our patients was (57.79 
± 18.43 years), and most of them had comorbid 
conditions (83%), we suggest that prophylactic 
measures should be taken to prevent the develop-
ment of LRTI in those patients. Several vaccines, 
including influenza and pneumococcal vaccines, 
are recommended for the elderly. Pneumococcal 
vaccinesare highly recommended for chronic ob-
structive pulmonary disease patients in order to 
prevent pneumonia [49, 50]. In addition, the ad-
mitted patients must be continuously monitored, 
and CURB65 score must be calculated regularly, to 
predict any deterioration in the clinical course of 
LRTI, since the CURB-65 score has been validated 
for predicting morbidity and mortality in commun-
ity-acquired pneumonia [19]. 
Limitations
Our study showed a positive bacterial test result 
only in 21.1% of patients. The pathogen-detection 
rate is towards the lower end of etiologic studies of 
pneumonia in adults. Isolation of etiological agents 
ranged between 20% and 76% in other studies 
conducted around the world [21, 43, 51-57]. Po-
tential explanations for low detection yields in our 
study include low sensitivity of blood cultures [21], 
inability to obtain lower respiratory tract specimens, 
non-infectious causes (aspiration pneumonia), late 
presentation, partial treatment and antibiotic use 
before sample collection [51, 58].
Another limitation of our study was the lack of 
1-year follow-up to determine the one-year mortal-
ity rates of pneumonia. Most of our patients had 
multiple chronic illnesses, for which the one-year 
mortality rate after developing LRTI may approach 
40% [45, 59]. Further studies with one-year fol-
low-up period are encouraged, to study the long-
term morbidity and mortality of LRTI in Jordanian 
population. 
In conclusion, this current study demonstrated 
that the most prevalent organism identified to be 
associated with LRTI was S. aureus in Jordanian hos-
pitalized patients. We have found that the mortality 
rate of hospitalized patients with LRTI in JUH was 
3.64%, which can be decreased by early identifi-
cation and proper treatment of high-risk patients. 
The causative agents for lower respiratory tract in-
fections vary throughout the year. It was found to 
be more common in the winter season, especially in 
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January. The findings need to be replicated in similar 
settings in Jordan and possibly other countries in 
the region. 
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